Live

China retaliated with 34% tariffs on US goods, while Trump vows his policies will 'never change.'

NasdaqGM - Nasdaq Real Time Price USD

Artiva Biotherapeutics, Inc. (ARTV)

2.5400

-0.3200

(-11.19%)

At close: April 3 at 4:00:01 PM EDT

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT. Members of the Artiva management team will also be available to participate in invest

GlobeNewswire 3 days ago

ARTV
-11.19%
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIE

GlobeNewswire 10 days ago

ARTV
-11.19%
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate

GlobeNewswire last month

ARTV
-11.19%
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chie

GlobeNewswire 2 months ago

ARTV
-11.19%
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications expected H1 2025 Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clini

GlobeNewswire 4 months ago

ARTV
-11.19%
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK. Members of the Artiva management team will also be av

GlobeNewswire 4 months ago

ARTV
-11.19%
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensi

GlobeNewswire 5 months ago

ALLO

CDXS

ARTV
-11.19%
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT, in New York City, New York. Members of

GlobeNewswire 6 months ago

ARTV
-11.19%
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indicationsTreated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Art

GlobeNewswire 7 months ago

ARTV
-11.19%
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 8 months ago

ARTV
-11.19%
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the pricing of its upsized initial public offering of 13,920,000 shares of common stock at a price to the public of $12.00 per share. All of the shares of common stock are being offered by Artiva. The gross proceeds to

GlobeNewswire 8 months ago

ARTV
-11.19%

Performance Overview

Return	ARTV	S&P 500 (^GSPC)
YTD	-74.80%	-8.25%
1-Year	-84.13%	+3.55%
3-Year	-84.13%	+18.71%